Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Cytoplasmic TRADD confers a worse prognosis in glioblastoma.

Chakraborty S, Li L, Tang H, Xie Y, Puliyappadamba VT, Raisanen J, Burma S, Boothman DA, Cochran B, Wu J, Habib AA.

Neoplasia. 2013 Aug;15(8):888-97.

2.

Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.

Wang Z, Yang J, Xu G, Wang W, Liu C, Yang H, Yu Z, Lei Q, Xiao L, Xiong J, Zeng L, Xiang J, Ma J, Li G, Wu M.

Oncotarget. 2015 Feb 20;6(5):3147-64.

3.

Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma.

Rajbhandari R, McFarland BC, Patel A, Gerigk M, Gray GK, Fehling SC, Bredel M, Berbari NF, Kim H, Marks MP, Meares GP, Sinha T, Chuang J, Benveniste EN, Nozell SE.

Oncotarget. 2015 Jul 10;6(19):17805-16.

4.

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.

Cheng Q, Ma X, Cao H, Chen Z, Wan X, Chen R, Peng R, Huang J, Jiang B.

Mol Med Rep. 2017 Feb;15(2):597-604. doi: 10.3892/mmr.2016.6078. Epub 2016 Dec 27.

5.

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.

Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R.

Neuro Oncol. 2013 Mar;15(3):269-78. doi: 10.1093/neuonc/nos301. Epub 2012 Dec 20.

6.

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.

Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G, Melchiorri D.

Cell Death Differ. 2013 Mar;20(3):396-407. doi: 10.1038/cdd.2012.150. Epub 2012 Nov 23.

7.

Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.

Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, Fulda S.

Cell Death Dis. 2013 Mar 28;4:e564. doi: 10.1038/cddis.2013.70.

8.

Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.

Li ZY, Li QZ, Chen L, Chen BD, Wang B, Zhang XJ, Li WP.

Neurochem Res. 2016 Dec;41(12):3192-3205. Epub 2016 Sep 8.

PMID:
27632183
9.

Y14 positively regulates TNF-α-induced NF-κB transcriptional activity via interacting RIP1 and TRADD beyond an exon junction complex protein.

Togi S, Shiga K, Muromoto R, Kato M, Souma Y, Sekine Y, Kon S, Oritani K, Matsuda T.

J Immunol. 2013 Aug 1;191(3):1436-44. doi: 10.4049/jimmunol.1300501. Epub 2013 Jul 1.

10.

Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.

Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z, Zhang Y, Gao Z, Zhu X.

Tumour Biol. 2014 Dec;35(12):12327-37. doi: 10.1007/s13277-014-2545-1. Epub 2014 Sep 23.

PMID:
25245332
11.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL.

Mol Cancer Res. 2016 Mar;14(3):302-12. doi: 10.1158/1541-7786.MCR-15-0183. Epub 2016 Jan 13.

12.

miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.

Haemmig S, Baumgartner U, Glück A, Zbinden S, Tschan MP, Kappeler A, Mariani L, Vajtai I, Vassella E.

Cell Death Dis. 2014 Jun 5;5:e1279. doi: 10.1038/cddis.2014.245.

14.

Oncrasin targets the JNK-NF-κB axis to sensitize glioma cells to TNFα-induced apoptosis.

Gupta P, Dixit D, Sen E.

Carcinogenesis. 2013 Feb;34(2):388-96. doi: 10.1093/carcin/bgs352. Epub 2012 Nov 3.

PMID:
23125226
15.

Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.

Munoz JL, Rodriguez-Cruz V, Ramkissoon SH, Ligon KL, Greco SJ, Rameshwar P.

Oncotarget. 2015 Jan 20;6(2):1190-201.

16.

A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.

Shukla S, Pia Patric IR, Thinagararjan S, Srinivasan S, Mondal B, Hegde AS, Chandramouli BA, Santosh V, Arivazhagan A, Somasundaram K.

Cancer Res. 2013 Nov 15;73(22):6563-73. doi: 10.1158/0008-5472.CAN-13-0298. Epub 2013 Sep 27.

17.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
18.

Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.

Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM.

J Biol Chem. 2013 Sep 6;288(36):26167-76. doi: 10.1074/jbc.M113.477950. Epub 2013 Jul 31.

19.

RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.

Yeom SY, Nam DH, Park C.

Mol Cancer Ther. 2014 Dec;13(12):3049-61. doi: 10.1158/1535-7163.MCT-14-0244. Epub 2014 Oct 13.

20.

Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.

Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X.

Int J Oncol. 2016 Feb;48(2):559-68. doi: 10.3892/ijo.2015.3271. Epub 2015 Nov 27.

PMID:
26648123

Supplemental Content

Support Center